D
Derek L. Clouthier
Researcher at Princess Margaret Cancer Centre
Publications - 7
Citations - 369
Derek L. Clouthier is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Pembrolizumab & Cancer. The author has an hindex of 4, co-authored 7 publications receiving 138 citations.
Papers
More filters
Journal ArticleDOI
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman,Scott V. Bratman,S. Y. Cindy Yang,S. Y. Cindy Yang,Marco A. J. Iafolla,Marco A. J. Iafolla,Zhihui Liu,Zhihui Liu,Aaron R. Hansen,Aaron R. Hansen,Philippe L. Bedard,Philippe L. Bedard,Stephanie Lheureux,Stephanie Lheureux,Anna Spreafico,Anna Spreafico,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Svetlana Shchegrova,Maggie C. Louie,Paul Billings,Bernhard Zimmermann,Himanshu Sethi,Alexey Aleshin,Dax Torti,Kayla Marsh,Jenna Eagles,Iulia Cirlan,Youstina Hanna,Derek L. Clouthier,Scott C. Lien,Scott C. Lien,Pamela S. Ohashi,Pamela S. Ohashi,Wei Xu,Wei Xu,Lillian L. Siu,Lillian L. Siu,Trevor J. Pugh,Trevor J. Pugh +39 more
TL;DR: The potential for broad clinical utility of ctDNA-based surveillance in patients treated with ICB is demonstrated, and 12 patients with ct DNA clearance during treatment were alive with median 25 months follow up.
Journal ArticleDOI
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
S. Y. Cindy Yang,S. Y. Cindy Yang,Stephanie Lheureux,Stephanie Lheureux,Katherine Karakasis,Julia V. Burnier,Jeff Bruce,Derek L. Clouthier,Arnavaz Danesh,Rene Quevedo,Rene Quevedo,Mark Dowar,Youstina Hanna,Tiantian Li,Lin Lu,Wei Xu,Blaise A. Clarke,Blaise A. Clarke,Pamela S. Ohashi,Pamela S. Ohashi,Patricia Shaw,Patricia Shaw,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh,Amit M. Oza,Amit M. Oza +26 more
TL;DR: An integrated clinical, exome, and transcriptome analysis of 41 primary tumors from LT and ST HGSOC patients suggested that exceptional long- or short-term survival is determined by a concert of clinical, molecular, and microenvironment factors.
Posted ContentDOI
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
S. Y. Cindy Yang,Scott C. Lien,Ben X. Wang,Derek L. Clouthier,Youstina Hanna,Iulia Cirlan,Kelsey Zhu,Jeff Bruce,Samah El Ghamrasni,Marco A. J. Iafolla,Marc Oliva,Aaron R. Hansen,Anna Spreafico,Philippe L. Bedard,Stephanie Lheureux,Albiruni Ryan Abdul Razak,Vanessa Speers,Hal K. Berman,Alexey Aleshin,Benjamin Haibe-Kains,David G. Brooks,David G. Brooks,Tracy L. McGaha,Tracy L. McGaha,Marcus O. Butler,Marcus O. Butler,Scott V. Bratman,Scott V. Bratman,Pamela S. Ohashi,Pamela S. Ohashi,Lillian L. Siu,Trevor J. Pugh,Trevor J. Pugh,Trevor J. Pugh +33 more
TL;DR: In this paper, the authors presented an in-depth analysis of clinical, whole-exome, transcriptome, and ctDNA profiles of 73 patients with advanced solid tumors, across 30 cancer types, from a phase II basket clinical trial of pembrolizumab (NCT02644369) and report changes in genomic and immune landscapes (primary outcomes).
Journal ArticleDOI
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
Derek L. Clouthier,Scott C. Lien,Scott C. Lien,S. Y. Cindy Yang,Linh T. Nguyen,Venkata S. K. Manem,Venkata S. K. Manem,Diana Gray,Michael Ryczko,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak,Jeremy Lewin,Stephanie Lheureux,Stephanie Lheureux,Ilaria Colombo,Philippe L. Bedard,Philippe L. Bedard,David Cescon,David Cescon,Anna Spreafico,Anna Spreafico,Marcus O. Butler,Marcus O. Butler,Aaron R. Hansen,Aaron R. Hansen,Raymond Jang,Raymond Jang,Sangeet Ghai,Sangeet Ghai,Ilan Weinreb,Valentin Sotov,Ramy Gadalla,Babak Noamani,Mengdi Guo,Mengdi Guo,Sawako Elston,Amanda Giesler,Sevan Hakgor,Haiyan Jiang,Tracy L. McGaha,Tracy L. McGaha,David G. Brooks,David G. Brooks,Benjamin Haibe-Kains,Trevor J. Pugh,Trevor J. Pugh,Pamela S. Ohashi,Pamela S. Ohashi,Lillian L. Siu,Lillian L. Siu +49 more
TL;DR: Tissue biopsies provide distinct data from the blood and may predict response to pembrolizumab and provide technical feasibility data for correlative studies, as well as evaluating associations with treatment response.
Journal ArticleDOI
Costimulation, a surprising connection for immunotherapy
TL;DR: Important mechanisms of checkpoint blockade are elucidated by demonstrating that PD-1 exerts its primary effect of dampening T cell activation by regulating a T cell receptor costimulatory molecule called cluster of differentiation 28 (CD28).